SITC 2024: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy

SITC 2024: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy

Summary:

• B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines demonstrate overexpression of the human HER2 protein.
• B-hHER2 MC38 plus and B-hHER2 CT26.WT cell lines exhibit normal tumor growth in B-hHER2 and BALB/c mice, respectively.
• Treatment with 10 mg/kg Trastuzumab analog-MMAE and 5 mg/kg DS8201 fully inhibited B-hHER2 MC38 plus growth in vivo.
• 10 mg/kg Trastuzumab analog-MMAE significantly inhibited B-hHER2 CT26.WT growth in vivo.
• Both HER2-humanized cell lines form syngeneic mouse tumor models ideal for in vivo HER2 ADC pharmacodynamic studies.